SecBot SecBot
SECBOTREPLAY Home › Report › INVA

INVA · Innoviva, Inc

Innoviva, Inc. · 10-K/A filed Mar 27, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 3/10

10-K/A filed Mar 27, 2026 at 16:01 ET

Innoviva, Inc. filed an amended 10-K to include the audited consolidated financial statements of its majority-owned subsidiary, Armata Pharmaceuticals, Inc., which were not available at the time of the original filing. The amendment is routine and does not reflect changes to Innoviva's own financial statements or operations.

  • The 10-K/A filing is an amendment to include Armata Pharmaceuticals' audited financial statements as required by Rule 3-09 of Regulation S-X.
  • Armata is a clinical-stage biotechnology company focused on bacteriophage therapeutics, in which Innoviva holds a 68.8% ownership stake.
  • The amendment was necessary because Armata's financial statements were not available when the original 10-K was filed on February 25, 2026.
  • The explanatory note confirms that no other disclosures in the original filing have been updated or changed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access